Multiparticulate systems containing 5-aminosalicylic acid for the treatment of inflammatory bowel disease

References

• Hanauer SB. (2006). Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis, 12 (Suppl 1):S3–S9.
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Sandborn WJ. (2007). Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet, 369:1641–1657.
   PubMed Web of Science ®Google Scholar
• Fiocchi C. (2002). Inflammatory bowel disease. Current concepts of pathogenesis and implications for therapy. Minerva Gastroenterol Dietol, 48:215–226.
   PubMedGoogle Scholar
• Elson CO, Sartor RB, Targan SR, Sandborn WJ. (2003). Challenges in IBD Research: updating the scientific agendas. Inflamm Bowel Dis, 9:137–153.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR. (2009). Mesalamine in the treatment of ulcerative colitis: novel therapeutic options. Gastroenterol Hepatol, 5:65–73.
   Google Scholar
• D’Haens G, Hommes D, Engels L, Baert F, van der Waaij L, Connor P et al. (2006). Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. Aliment Pharmacol Ther, 24:1087–1097.
   PubMed Web of Science ®Google Scholar
• Ando T, Watanabe O, Nobata K, Ishiguro K, Maeda O, Ishikawa D et al. (2008). Immunological status of the stomach in inflammatory bowel disease—comparison between ulcerative colitis and Crohn’s disease. Digestion, 77:145–149.
   PubMed Web of Science ®Google Scholar
• Gariballa SE, Gunasekera NP. (1994). Bilateral foot drop, weight loss and rectal bleeding as an acute presentation of Crohn’s disease. Postgrad Med J, 70:762–763.
   PubMed Web of Science ®Google Scholar
• Tresca AJ. (2009). The differences between ulcerative colitis and Crohn’s disease. About.com Guide [Online]. Available at: http://ibdcrohns.about.com/od/ulcerativecolitis/a/diffuccd.htm. Updated on May 2, 2009.
   Google Scholar
• Low RN, Sebrechts CP, Politoske DA, Bennett MT, Flores S, Snyder RJ et al. (2002). Crohn disease with endoscopic correlation: single-shot fast spin-echo and gadolinium-enhanced fat-suppressed spoiled gradient-echo MR imaging. Radiology, 222:652–660.
   PubMed Web of Science ®Google Scholar
• Guthery SL. (2007). Inflammatory bowel disease as a complex genetic disease [Online]. Available at: http://jorde-lab.genetics.utah.edu/medstudents_2007/Guthery_IBD_lecture.pdf
   Google Scholar
• Wijmenga C. (2005). Expressing the differences between Crohn disease and ulcerative colitis. Plos Med, 2:e230; quiz e304.
   PubMed Web of Science ®Google Scholar
• Frieri G, Giacomelli R, Pimpo M, Palumbo G, Passacantando A, Pantaleoni G et al. (2000). Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. Gut, 47:410–414.
   PubMed Web of Science ®Google Scholar
• Rudolph MW, Klein S, Beckert TE, Petereit H, Dressman JB. (2001). A new 5-aminosalicylic acid multi-unit dosage form for the therapy of ulcerative colitis. Eur J Pharm Biopharm, 51:183–190.
   PubMed Web of Science ®Google Scholar
• Farup PG, Hinterleitner TA, Lukás M, Hébuterne X, Rachmilewitz D, Campieri M et al. (2001). Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflamm Bowel Dis, 7:237–242.
   PubMed Web of Science ®Google Scholar
• Hawthorne AB, Rubin G, Ghosh S. (2008). Review article: medication non-adherence in ulcerative colitis—strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Ther, 27:1157–1166.
   PubMed Web of Science ®Google Scholar
• Shale MJ, Riley SA. (2003). Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther, 18:191–198.
   PubMed Web of Science ®Google Scholar
• Han SW, McColl E, Barton JR, James P, Steen IN, Welfare MR. (2005). Predictors of quality of life in ulcerative colitis: the importance of symptoms and illness representations. Inflamm Bowel Dis, 11:24–34.
   PubMed Web of Science ®Google Scholar
• Lakatos PL, Lakatos L. (2008). Once daily 5-aminosalicylic acid for the treatment of ulcerative colitis; are we there yet? Pharmacol Res, 58:190–195.
   PubMed Web of Science ®Google Scholar
• Prantera C, Rizzi M. (2009). 5-ASA in ulcerative colitis: improving treatment compliance. World J Gastroenterol, 15:4353–4355.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ. (2008). Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations? J Clin Gastroenterol, 42:338–344.
   PubMed Web of Science ®Google Scholar
• Egan LJ, Sandborn WJ. (1998). Drug therapy of inflammatory bowel disease. Drugs Today, 34:431–446.
   PubMed Web of Science ®Google Scholar
• Talero E, Sánchez-Fidalgo S, Calvo JR, Motilva V. (2007). Chronic administration of galanin attenuates the TNBS-induced colitis in rats. Regul Pept, 141:96–104.
   PubMed Web of Science ®Google Scholar
• Sands BE. (2000). Therapy of inflammatory bowel disease. Gastroenterology, 118:S68–S82.
   PubMed Web of Science ®Google Scholar
• Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott RP et al. (1993). Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease. Clin Exp Immunol, 94:174–181.
   PubMed Web of Science ®Google Scholar
• Cabrero A, Laguna JC, Vázquez M. (2002). Peroxisome proliferator-activated receptors and the control of inflammation. Curr Drug Targets Inflamm Allergy, 1:243–248.
   PubMedGoogle Scholar
• Hanauer SB. (2004). Medical therapy for ulcerative colitis 2004. Gastroenterology, 126:1582–1592.
   PubMed Web of Science ®Google Scholar
• Kornbluth A, Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. (2004). Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol, 99:1371–1385.
   PubMed Web of Science ®Google Scholar
• Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG. (1997). Oral budesonide is as effective as oral prednisolone in active Crohn’s disease. The Global Budesonide Study Group. Gut, 41:209–214.
   PubMed Web of Science ®Google Scholar
• van Dieren JM, Kuipers EJ, Samsom JN, Nieuwenhuis EE, van der Woude CJ. (2006). Revisiting the immunomodulators tacrolimus, methotrexate, and mycophenolate mofetil: their mechanisms of action and role in the treatment of IBD. Inflamm Bowel Dis, 12:311–327.
   PubMed Web of Science ®Google Scholar
• Markowitz J. (2008). Current treatment of inflammatory bowel disease in children. Dig Liver Dis, 40:16–21.
   PubMedGoogle Scholar
• Kruis W, Bar-Meir S, Feher J, Mickisch O, Mlitz H, Faszczyk M et al. (2003). The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol, 1:36–43.
   PubMed Web of Science ®Google Scholar
• Sutherland L, Macdonald JK. (2006). Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev, 4: CD000543.
   Google Scholar
• Bernstein CN, Eaden J, Steinhart AH, Munkholm P, Gordon PH. (2002). Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid. Inflamm Bowel Dis, 8:356–361.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB. (2003). Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther, 17:29–42.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ. (2007). New advances in 5-ASA therapy for ulcerative colitis. Medscape gastroenterology [Online]. Available at: http://cme.medscape.com/viewarticle/553568. Accessed on March 3, 2007.
   Google Scholar
• Pierce D, Martin P, Kern M, Homolka R. (2007). MMX™ Mesalazine: a pharmacokinetic evaluation of dose proportionality and the effect of food. Gut, 56 (Suppl 3):A158.
   Google Scholar
• Ng SC, Kamm MA. (2008). Review article: new drug formulations, chemical entities and therapeutic approaches for the management of ulcerative colitis. Aliment Pharmacol Ther, 28:815–829.
   PubMed Web of Science ®Google Scholar
• Brunner M, Greinwald R, Kletter K, Kvaternik H, Corrado ME, Eichler HG et al. (2003). Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers. Aliment Pharmacol Ther, 17:1163–1169.
   PubMed Web of Science ®Google Scholar
• Chourasia MK, Jain SK. (2003). Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharm Sci, 6:33–66.
   PubMed Web of Science ®Google Scholar
• Leopold CS. (1999). Coated dosage forms for colon-specific drug delivery. Pharm Sci Technol Today, 2:197–204.
   PubMedGoogle Scholar
• Marakhouski Y, Fixa B, Holomán J, Hulek P, Lukas M, Bátovský M et al.; International Salofalk Study Group. (2005). A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Aliment Pharmacol Ther, 21:133–140.
   PubMed Web of Science ®Google Scholar
• Kles KA, Vavricka SR, Turner JR, Musch MW, Hanauer SB, Chang EB. (2005). Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum. Inflamm Bowel Dis, 11:253–257.
   PubMed Web of Science ®Google Scholar
• Loftus EV Jr, Kane SV, Bjorkman D. (2004). Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther, 19:179–189.
   PubMed Web of Science ®Google Scholar
• Harrell LE, Hanauer SB. (2004). Mesalamine derivatives in the treatment of Crohn’s disease. Gastroenterol Clin North Am, 33:303–17, ix.
   PubMed Web of Science ®Google Scholar
• Khan MZ, Prebeg Z, Kurjakovic N. (1999). A pH-dependent colon targeted oral drug delivery system using methacrylic acid copolymers. I. Manipulation of drug release using Eudragit L100-55 and Eudragit S100 combinations. J Control Release, 58:215–222.
   PubMed Web of Science ®Google Scholar
• Asghar LF, Chandran S. (2006). Multiparticulate formulation approach to colon specific drug delivery: current perspectives. J Pharm Pharm Sci, 9:327–338.
   PubMed Web of Science ®Google Scholar
• Yang L, Chu JS, Fix JA. (2002). Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation. Int J Pharm, 235:1–15.
   PubMed Web of Science ®Google Scholar
• Burakoff R. (2000). Crohn’s disease of the small intestine. Curr Treat Options Gastroenterol, 3:59–68.
   Google Scholar
• Klotz U. (2005). Colonic targeting of aminosalicylates for the treatment of ulcerative colitis. Dig Liver Dis, 37:381–388.
   PubMedGoogle Scholar
• Sinha VR, Kumria R. (2004). Polysaccharide matrices for microbially triggered drug delivery to the colon. Drug Dev Ind Pharm, 30:143–150.
   PubMed Web of Science ®Google Scholar
• Linskens RK, Huijsdens XW, Savelkoul PH, Vandenbroucke-Grauls CM, Meuwissen SG. (2001). The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics. Scand J Gastroenterol, 36(Suppl): 29–40.
   Google Scholar
• Lee CM, Kim DW, Lee HC, Lee KY. (2004). Pectin microspheres for oral colon delivery: preparation using spray drying method and in vitro release of indomethacin. Biotechnol Bioprocess Eng, 9:191–195.
   Web of Science ®Google Scholar
• Ji CM, Xu HN, Wu W. (2009). Guar gum as potential film coating material for colon-specific delivery of fluorouracil. J Biomater Appl, 23:311–329.
   PubMed Web of Science ®Google Scholar
• Siew LF, Man SM, Newton JM, Basit AW. (2004). Amylose formulations for drug delivery to the colon: a comparison of two fermentation models to assess colonic targeting performance in vitro. Int J Pharm, 273:129–134.
   PubMed Web of Science ®Google Scholar
• Ferrari PC, Oliveira GF, Chibebe FCS, Evangelista RC. (2009). In vitro characterization of coevaporates containing chitosan for colonic drug delivery. Carbohydr Polym, 78:557–563.
   Web of Science ®Google Scholar
• Zhao W, Song L, Deng H, Yao H. (2009). Hydration, erosion, and release behavior of guar-based hydrophilic matrix tablets containing total alkaloids of Sophora alopecuroides. Drug Dev Ind Pharm, 35:594–602.
   PubMed Web of Science ®Google Scholar
• Edwards C. (1993). Interactions between nutrition and the intestinal microflora. Proc Nutr Soc, 52:375–382.
   PubMed Web of Science ®Google Scholar
• Cheng G, An F, Zou MJ, Sun J, Hao XH, He YX. (2004). Time- and pH-dependent colon-specific drug delivery for orally administered diclofenac sodium and 5-aminosalicylic acid. World J Gastroenterol, 10:1769–1774.
   PubMed Web of Science ®Google Scholar
• Abrahamsson B, Alpsten M, Jonsson UE, Lundberg PJ, Sandberg A, Sundgren M et al. (1996). Gastro-intestinal transit of a multiple-unit formulation (metoprolol CR/ZOK) and a non-disintegrating tablet with the emphasis on colon. Int J Pharm, 140:229–235.
   Web of Science ®Google Scholar
• Zhang H, Alsarra IA, Neau SH. (2002). An in vitro evaluation of a chitosan-containing multiparticulate system for macromolecule delivery to the colon. Int J Pharm, 239:197–205.
   PubMed Web of Science ®Google Scholar
• Wilding IR, Kenyon CJ, Hooper G. (2000). Gastrointestinal spread of oral prolonged-release mesalazine microgranules (Pentasa) dosed as either tablets or sachet. Aliment Pharmacol Ther, 14:163–169.
   PubMed Web of Science ®Google Scholar
• Raedler A, Behrens C, Bias P. (2004). Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis—results from a randomized–controlled trial. Aliment Pharmacol Ther, 20:1353–1363.
   PubMed Web of Science ®Google Scholar
• Wiersma H, Escher JC, Dilger K, Trenk D, Benninga MA, van Boxtel CJ et al. (2004). Pharmacokinetics of mesalazine pellets in children with inflammatory bowel disease. Inflamm Bowel Dis, 10:626–631.
   PubMed Web of Science ®Google Scholar
• Kramar A, Turk S, Vrecer F. (2003). Statistical optimisation of diclofenac sustained release pellets coated with polymethacrylic films. Int J Pharm, 256:43–52.
   PubMed Web of Science ®Google Scholar
• Ghebre-Sellassie I. (1989). Pellets: a general overview. In: Ghebre-Sellassie I, ed. Pharmaceutical Pelletization Technology. New York: Marcel Dekker, pp. 1–13.
   Google Scholar
• Gryczová E, Dvořáčková K, Rabišková M. (2009). Evaluation of pellet friability. Čes Slov Farm, 58:9–13.
   Google Scholar
• Pérez J, Rabisková M. (2002). Influence of the drying technique on theophylline pellets prepared by extrusion–spheronization. Int J Pharm, 242:349–351.
   PubMed Web of Science ®Google Scholar
• Häring A, Vetchý D, Janovská L, Krejcová K, Rabisková M. (2008). Differences in characteristics of pellets prepared by different pelletization methods. Drug Dev Ind Pharm, 34:289–296.
   PubMed Web of Science ®Google Scholar
• Krejcová K, Rabisková M, Vetchý D, Polásek E, Tomásek V, Prokopová A. (2006). The influence of drug solubility and particle size on the pellet formulation in a rotoprocessor. Drug Dev Ind Pharm, 32:585–593.
   PubMed Web of Science ®Google Scholar
• Gu L, Liew CV, Heng PW. (2004). Wet spheronization by rotary processing—a multistage single-pot process for producing spheroids. Drug Dev Ind Pharm, 30:111–123.
   PubMed Web of Science ®Google Scholar
• Vehring R. (2008). Pharmaceutical particle engineering via spray drying. Pharm Res, 25:999–1022.
   PubMed Web of Science ®Google Scholar
• Emås M, Nyqvist H. (2000). Methods of studying aging and stabilization of spray-congealed solid dispersions with carnauba wax. 1. Microcalorimetric investigation. Int J Pharm, 197:117–127.
   PubMed Web of Science ®Google Scholar
• Gupta VK, Beckert TE, Price JC. (2001). A novel pH- and time-based multi-unit potential colonic drug delivery system. I. Development. Int J Pharm, 213:83–91.
   PubMed Web of Science ®Google Scholar
• Zambito Y, Di Colo G. (2003). Preparation and in vitro evaluation of chitosan matrices for colonic controlled drug delivery. J Pharm Pharm Sci, 6:274–281.
   PubMed Web of Science ®Google Scholar
• Roda A, Simoni P, Roda G, Caponi A, Pastorini E, Locatelli M et al. (2009). Pharmacokinetics and safety of a new 1200 mg single-dose delayed release mesalazine microgranule formulation. J Bioequiv Bioavail, 1:44–51.
   Google Scholar
• Press AG, Hauptmann IA, Hauptmann L, Fuchs B, Fuchs M, Ewe K et al. (1998). Gastrointestinal pH profiles in patients with inflammatory bowel disease. Aliment Pharmacol Ther, 12:673–678.
   PubMed Web of Science ®Google Scholar
• Milojevic S, Newton JM, Cummings JH, Gibson GR, Botham RL, Ring SG et al. (1996). Amylose as a coating for drug delivery to the colon: preparation and in vitro evaluation using 5-aminosalicylic acid pellets. J Control Release, 38:75–84.
   Web of Science ®Google Scholar
• Lin SY, Ayres JW. (1992). Calcium alginate beads as core carriers of 5-aminosalicylic acid. Pharm Res, 9:1128–1131.
   PubMed Web of Science ®Google Scholar
• Karrout Y, Neut C, Wils D, Siepmann F, Deremaux L, Flament MP et al. (2009). Novel polymeric film coatings for colon targeting: drug release from coated pellets. Eur J Pharm Sci, 37:427–433.
   PubMed Web of Science ®Google Scholar
• Karrout Y, Neut C, Wils D, Siepmann F, Deremaux L, Dubreuil L et al. (2009). Colon targeting with bacteria-sensitive films adapted to the disease state. Eur J Pharm Biopharm, 73:74–81.
   PubMed Web of Science ®Google Scholar
• Dvořáčková K, Bautzová T, Rabišková M. (2011). Dissolution study in the evaluation of oral preparations with controlled drug release. Chem Listy, 105:50–54.
   Web of Science ®Google Scholar
• Strober W, Lúdvíksson BR, Fuss IJ. (1998). The pathogenesis of mucosal inflammation in murine models of inflammatory bowel disease and Crohn disease. Ann Intern Med, 128:848–856.
   PubMed Web of Science ®Google Scholar
• Lamprecht A, Ubrich N, Yamamoto H, Schäfer U, Takeuchi H, Maincent P et al. (2001). Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther, 299:775–781.
   PubMed Web of Science ®Google Scholar
• Wei H, Li-Fang F, Min B, Yong-Zhen C, Bai X, Qing D et al. (2010). Chitosan/Kollicoat SR 30D film-coated pellets of aminosalicylates for colonic drug delivery. J Pharm Sci, 99:186–195.
   PubMed Web of Science ®Google Scholar
• Mladenovska K, Raicki RS, Janevik EI, Ristoski T, Pavlova MJ, Kavrakovski Z et al. (2007). Colon-specific delivery of 5-aminosalicylic acid from chitosan–Ca-alginate microparticles. Int J Pharm, 342:124–136.
   PubMed Web of Science ®Google Scholar
• Bautzová T, Rabišková M, Lamprecht A. (2011). Mucoadhesive pellets for the treatment of inflammatory bowel disease. Int J Pharm, in press.
   PubMedGoogle Scholar
• Seo SB, Jeong HJ, Chung HS, Lee JD, You YO, Kajiuchi T et al. (2003). Inhibitory effect of high molecular weight water-soluble chitosan on hypoxia-induced inflammatory cytokine production. Biol Pharm Bull, 26:717–721.
   PubMed Web of Science ®Google Scholar
• Kim KW, Thomas RL. (2007). Antioxidative activity of chitosans with varying molecular weights. Food Chem, 101:308–313.
   Web of Science ®Google Scholar
• Klotz U. (1995). [5-Aminosalicylic acid and chronic inflammatory bowel diseases in children]. Klin Pediatr, 207:285–287.
   PubMedGoogle Scholar
• Evonik Industries. (2009). Eudragit® Application Guidelines, 11th Ed. Darmstadt: Evonik.
   Google Scholar
• Cohen RD, Lichtenstein GR, Safdi AV. (2008). 5-ASA treatment for ulcerative colitis: what’s on the horizon? Gastroenterol Hepatol, 11 (Suppl 24):5–14.
   Google Scholar
• Grosso A. (2009). A review of mesalazine MR formulations in ulcerative colitis. Br J Clin Pharm, 1:333–336.
   Google Scholar